Quote | Verve Therapeutics Inc. (NASDAQ:VERV)
Last: | $5 |
---|---|
Change Percent: | 0.6% |
Open: | $4.95 |
Close: | $5 |
High: | $5.09 |
Low: | $4.8 |
Volume: | 1,188,260 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Verve Therapeutics Inc. (NASDAQ:VERV)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-27 10:17:45 ET Information Technology has been the best performing name among all 11 S&P 500 ( SP500 ) sectors in the first half of 2024, but Cathie Wood’s actively managed ARK Innovation ETF ( NYSEARCA: ARKK ) - which aims to provide investors exposure to dis...
Message Board Posts | Verve Therapeutics Inc. (NASDAQ:VERV)
Subject | By | Source | When |
---|---|---|---|
https://cathiesark.com/ | TheFinalCD | investorshub | 02/15/2023 12:03:17 AM |
$VERV IS A GREAT $$$$$ OPPORTUNITY. | crudeoil24 | investorshub | 06/23/2022 7:55:13 PM |
Verve Therapeutics started at outperform with $48 stock | crudeoil24 | investorshub | 06/23/2022 11:26:25 AM |
Verve Therapeutics, Inc. is a genetic medicines company, | crudeoil24 | investorshub | 06/23/2022 11:19:31 AM |
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approac...